Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials. Those with low-risk disease may be able to avoid chemotherapy and its associated side effects.
Methods for ctDNA detection require very high-sensitivity approaches in order to detect microscopic disease after surgery or treatment. Methods have been developed that utilize genomic profiling of tumor tissue based on patient-specific next-generation sequencing (NGS) panels. High-sensitivity personalized panels allow detection of residual disease and serial monitoring for detection of recurrence.
This webinar will discuss the use of such panels to test for residual disease and recurrence in the treatment of colorectal cancer.